{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174982","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.228076+00:00","generated_at":"2026-05-17T18:15:35.714700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M","bullets":["On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.","Concluding FREEDOM trial after 15 mg/kg cohort; transitioning sites to Phase 2 MAD study FREEDOM2-DM1.","Cash $74.7M sufficient into Q2 2026; net loss $23.1M ($0.70/sh) vs $28.3M ($0.87/sh) YoY.","Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025.","FREEDOM2 5 mg/kg cohort results expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174982","json":"https://secwatch.observer/filing/0001193125-25-174982.json","markdown":"https://secwatch.observer/filing/0001193125-25-174982.md","text":"https://secwatch.observer/filing/0001193125-25-174982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/0001193125-25-174982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/pepg-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:15:35.714700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}